Novo Nordisk to Further Develop New Obesity Drugs, Expand Treatment Portfolio
Wall Street Journal
Novo Nordisk, the maker of blockbuster drugs Ozempic and Wegovy, is expanding into areas like cardiovascular diseases and increasing focus on treating conditions outside of its core diabetes and weight-loss market.